STOCKHOLM--(BUSINESS WIRE)--Regulatory News: MEDA (STO:MEDAA): Meda licensed the exclusive rights to Elidel (pimecrolimus 1% cream) and Xerese (acyclovir and hydrocortisone cream) to Valeant in North America. The companies will collaborate on development of the products.